Immunomodulatory Peptides with High Binding Affinity for Class IIMHC Molecules for the Prevention of Graft-Versus-Host Disease

Leukemia and Lymphoma

Volumn 23, Issue 42006, 1996, Pages 11-16

  Schlegel, Paul G ^a   Chao, Nelson J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

class II binding peptides; class II MHC; competitive inhibition; GVHD; half life; minor histocompatibility antigens; prevention of GVHD

Indexed keywords

IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; BINDING AFFINITY; COMPETITIVE INHIBITION; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-ANTIBODY REACTIONS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES;

EID: 0029804834     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609054796     Document Type: Article

References (47)

1. Forman S. J., Blume K. G., Thomas D. E. Bone marrow transplantation. Oxford University Press, Oxford 1994
2. Chao N. J., Schmidt G. M., Niland J. C., Amylon M. D., Dagis A. C., Long G. D., Nademanee A. P., Negrin R. S., O'Donnell M. R., Parker P. M., Smith E. P., Snyder D. S., Stein A. S., Wong R. M., Blume K. G., Forman S. F. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New England Journal of Medicine 1993; 329: 1225 – 1230
3. Chao N. J., Schlegel P. G. Prevention and treatment of graft-versus-host disease. Annals of the New York Academy of Sciences 1995, in press
4. Billingham R. The biology of graft-versus-host reaction. Harvey Lecture 1966; 21
5. Sakamoto H., Michaelson J., Jones W. K., Bhan A. K., Abhyankar S., Silverstein M., Golan D. E., Burakoff S., Ferrara J. L. M. Lymphocytes with a CD4+CD8-CD3- phenotype are effectors of experimental graft-versus-host disease. Proc. Natl. Acad. Sci. USA 1991; 88: 10890 – 10894
6. Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51 – 58
7. Hamilton B. L. L3T4-positive cells participate in the induction of graft-versus-host disease in response to minor histocompatibility antigens. J. Immunol. 1987; 139: 2511 – 2515
8. Korngold R., Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med. 1987; 165: 1552 – 1564
9. Parkman R. Clonal analysis of murine graft-versus-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J. Immunol. 1986; 136: 3543 – 3548
10. Korngold R. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant 1992; 9: 355 – 364
11. Korngold R., Sprent J. T-cell subsets in graft-vs.-host disease. Graft-vs.-Host Disease. Immunology, Pathophysiology, and Treatment, S. J. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Marcel Dekker, New York 1990; 31 – 49
12. Shenoy S., Mohanakumar T. MHC class II in β2-microglobulin deficient mice following bone marrow transplantation. The 9th International Congress of Immunology. 1995; A428, Graft versus host disease is mediated through
13. Perreault C., Décary F., Brochu S., Gyger M., Bélanger R., Roy D. Minor histocompatibility antigens. Blood 1990; 76: 1269 – 1280
14. Griem P., Wallny H. J., Falk K., Rötzschke O., Arnold B., Schönrich G., Hämmerling G., Rammensee H. G. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 1991; 65: 633 – 640
15. Den Haan J. M., Sherman N. E., Blokland E., Huczko E., Koning F., Drijfhout J. W., Skipper J., Shabanowitz J., Hunt D. F., Engelhard V. H., Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476 – 80
16. Wang W., Meadows L. R., Den Haan J. M. M., Sherman N. E., Chen Y., Blokland E., Shabanowitz J., Agulnik A. I., Hendrickson R. C., Bishop C. E., Hunt D. F., Goulmy E., Engelhard V. H. Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588 – 1590
17. Speiser D. E., Zürcher T., Ramseier H., Hengartner H., Staeheli P., Haller O., Zinkernagel R. M. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen. Proc. Natl. Acad. Sci. USA 1990; 87: 2021 – 2025
18. Wallny P. J., Rammensee H. G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343: 275 – 278
19. Roopenian D. C., Christianson G. J., Davis A. P., Zuberi A. R., Mobraaten L. E. The genetic origin of minor histocompatibility antigens. Immunogenetics 1993; 38: 131 – 140
20. Hunt D. F., Michel H., Dickinson T. A., Shabanowitz J., Cox A. L., Sakaguchi K., Appella E., Grey H. M., Sette A. Peptides presented to the immune system by the murine class II MHC molecule I-Ad. Science 1992; 256: 1817 – 1820
21. Nestel F. P., Price K. S., Seemayer T. A., Lapp W. S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 1992; 175: 405 – 13
22. Piguet P. F., Grau G. E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 1987; 166: 1280 – 1289
23. McCarthy P. L., Jr., Abhyankar S., Neben S., Newman G., Sieff C., Thompson R. C., Burakoff S. J., Ferrara J. L. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915 – 1918
24. Rus V., Svetic A., Nguyen P., Gause W. C., Via C. S. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J. Immunol. 1995; 155: 2396 – 2406
25. Schlegel P. G., Aharoni R., Smilek D. E., Fernandez L. P., McDevitt H. O., Tran N., Vaysburd M., Chao N. J. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84: 2802 – 2810
26. Schlegel P. G., Aharoni R., Vaysburd M., Tran N., McDevitt H. O., Chao N. J. Inhibition of secondary MLR and prevention of murine graft-versus-host disease across minor histocompatibility barriers by peptides with high binding affinity for class II MHC molecules. FASEB 1994; 8: A478
27. Chao N. J. Graft-versus-host disease. Curr. Opin. Immunol. 1992; 4: 571 – 576
28. Blazar B. R., Taylor P. A., Panoskaltsis-Mortari A., Gray G. S., Vallera D. A. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995; 85: 2607 – 2618
29. Wallace P. M., Johnson J. S., Macmaster J. F., Kennedy K. A., Gladstone P., Linsley P. S. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602 – 610
30. Schlegel P. G., Vaysburd M., Chen Y., Butcher E., Chao N. J. Inhibition of T cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J. Immunol. 1995; 155: 3856 – 3865
31. Clayberger C., Krensky A. M. Immunosuppressive peptides corresponding to MHC class I sequences. Curr. Opin. Immunol. 1995, in press
32. Jameson B. A., McDonnell J. M., Marini J. C., Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 1994; 368: 744 – 746
33. Townsend R. M., Marini J. C., Jameson B. A., Korngold R. Efficacy of a CD4 peptide analog to treat GVHD during allogeneic bone marrow transplantation. The 9th International Congress of Immunology. 1995; A430
34. Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DRI. Nature 1993; 364: 33 – 39
35. Rudesnsly A. Y., Preston-Hurlburt P., Al-Ramadi B. K., Rothbard J., Janeway C. A. Truncation variants of peptides isolated from class II molecules suggest sequence motifs. Nature 1992; 359: 429 – 431
36. Babbitt B. P., Matsueda G., Haber E., Unanue E. R., Allen P. M. Antigenic competition at the level of peptide-Ia binding. Proc. Natl. Acad. Sci. USA 1986; 83: 4509 – 4513
37. Wraith D. C., Smilek D. E., Mitchell D. J., Steinman L., McDevitt H. O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell 1989; 59: 247 – 255
38. Gautam A. M., Pearson C. I., Smilek D. E., Steinman L., McDevitt H. O. A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J. Exp. Med. 1992; 176: 605 – 609
39. Smilek D. E., Lock C. B., McDevitt H. O. Antigen recognition and peptide-mediated immunotherapy to autoimmune disease. Immunol. Rev. 1990; 118: 37 – 71
40. Lamont A. G., Sette A., Fujinami R., Colon S. M., Miles C., Grey H. M. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for I-As molecules. J. Immunol. 1990; 145: 1687 – 1693
41. Fairchild P. J., Wildgoose R., Atherton E., Webb S., Wraith D. C. An autoantigenic T cell epitope forms unstable complexes with class II MHC: Anovel route for escape from tolerance induction. Int. Immunol. 1993; 5: 1151 – 58
42. Ishioka G. Y., Adorini L., Guery J. G., Gaeta F. C. A., Lafond R., Alexander J., Powell M. F., Sette A., Grey H. M. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. J. Immunol. 1994; 152: 4310 – 4319
43. Samson M. F., Smilek D. E. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 1995; 155: 2737 – 2746
44. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C. G. Amelioration autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491 – 1494
45. Sloan-Lancaster J., Evavold B. D., Allen P. M. Induction of T cell anergy by altered T cell receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156 – 159
46. Evavold B. D., Allen P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308 – 1310
47. Guery J. C., Adorini L. Selective immunosuppression of class II-restricted T cells by MHC class II-binding peptides. Crit. Rev. Immunol. 1993; 13: 195 – 206